This method was validated in 80 patients with FLT-ITD relapsed/refractory AML participating in a clinical trial of a novel FLT3 inhibitor, gilteritinib, and demonstrated a relationship between MRD measured by FLT3-ITD VAF and OS, with a detection threshold of 10−4. This evidence concerns the gene FLT1 and acute myeloid leukemia.